OmniAb, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
OmniAb reported Q3 2026 revenue of $4.0M (vs. $2.2M YoY), driven by service and xPloration revenue. Nine-month revenue reached $31.8M (vs. $10.3M YoY), primarily from milestone revenue. The company raised full-year 2026 revenue guidance to $35–$39M (from $32–$36M) and cash guidance to $53–$57M (from $49–$53M). In Q3, OmniAb signed a global collaboration with Eli Lilly for an ion channel program with up-front payment plus $370M in potential milestones and tiered royalties. The company also expanded commercial access to its xPloration platform (targets $500M+ market) and introduced OmniTides peptide discovery offering.
Why this rating
Raised guidance and $370M deal meaningful for $145M market cap; xPloration expansion and new platform launch indicate revenue diversification and growth trajectory.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.